BioCis Pharma Oy, Oy Lx Therapies join to form Laurantis Pharma Oy

The new company’s product portfolio comprises medicines targeting treatment of inflammatory diseases and conditions including atopic dermatitis, dry eye syndrome, interstitial cystitis, and lymphatic disorders, as well as the treatment of bladder cancer.

In connection with the formation of the new company, Riku Rautsola was appointed as president and CEO of Laurantis Pharma.

Rautsola said the formation of the new company provides an opportunity to build Laurantis Pharma from an early clinical development company to a successful specialty pharmaceutical company in the coming years.